Methods, outcomes, and costs of a 2.5 year comprehensive facility-and community-based HIV testing intervention in Bukoba Municipal Council, Tanzania, 2014-2017.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 06 11 2018
accepted: 07 04 2019
entrez: 4 5 2019
pubmed: 3 5 2019
medline: 11 1 2020
Statut: epublish

Résumé

To diagnose ≥90% HIV-infected residents (diagnostic coverage), the Bukoba Combination Prevention Evaluation (BCPE) implemented provider-initiated (PITC), home- (HBHTC), and venue-based (VBHTC) HIV testing and counseling (HTC) intervention in Bukoba Municipal Council, a mixed urban and rural lake zone community of 150,000 residents in Tanzania. This paper describes the methods, outcomes, and incremental costs of these HTC interventions. PITC was implemented in outpatient department clinics in all eight public and three faith-based health facilities. In clinics, lay counselors routinely screened and referred eligible patients for HIV testing conducted by HTC-dedicated healthcare workers. In all 14 wards, community teams offered HTC to eligible persons encountered at 31,293 home visits and at 79 male- and youth-frequented venues. HTC was recommended for persons who were not in HIV care or had not tested in the prior 90 days. BCPE conducted 133,695 HIV tests during the 2.5 year intervention (PITC: 88,813, 66%; HBHTC: 27,407, 21%; VBHTC: 17,475, 13%). Compared with other strategies, PITC conducted proportionally more tests among females (65%), and VBHTC conducted proportionally more tests among males (69%) and young-adults aged 15-24 years (42%). Of 5,550 (4.2% of all tests) HIV-positive tests, 4,143 (75%) clients were newly HIV diagnosed, including 1,583 males and 881 young adults aged 15-24 years. Of HIV tests conducted 3.7%, 1.8%, and 2.1% of PITC, HBHTC, and VBHTC clients, respectively, were newly HIV diagnosed; PITC accounted for 79% of all new diagnoses. Cost per test (per new diagnosis) was $4.55 ($123.66), $6.45 ($354.44), and $7.98 ($372.67) for PITC, HBHTC, and VBHTC, respectively. In a task-shifting analysis in which lay counselors replaced healthcare workers, estimated costs per test (per new diagnosis) would have been $3.06 ($83.15), $ 4.81 ($264.04), and $5.45 ($254.52), for PITC, HBHTC, and VBHTC, respectively. BCPE models reached different target groups, including men and young adults, two groups with consistently low coverage. Implementation of multiple models is likely necessary to achieve ≥90% diagnostic coverage.

Identifiants

pubmed: 31048912
doi: 10.1371/journal.pone.0215654
pii: PONE-D-18-32031
pmc: PMC6497243
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0215654

Subventions

Organisme : PEPFAR
Pays : United States

Déclaration de conflit d'intérêts

Author Johnita Byrd is employed by ICF International. ICF International was contracted by the U.S. Centers for Disease Control and Prevention to provide data management services only. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Références

J Int Assoc Provid AIDS Care. 2017 Nov/Dec;16(6):546-554
pubmed: 29117777
AIDS Behav. 2017 Aug;21(8):2551-2560
pubmed: 28299518
Sex Transm Infect. 2017 Jul;93(Suppl 3):
pubmed: 28736389
Trop Med Int Health. 2011 Jul;16(7):828-9
pubmed: 21418449
AIDS. 2014 Sep 10;28(14):2133-45
pubmed: 25062091
PLoS One. 2018 Dec 13;13(12):e0208919
pubmed: 30543693
Sex Transm Dis. 2013 Dec;40(12):909-14
pubmed: 24220349
J Acquir Immune Defic Syndr. 2016 Nov 01;73(3):e39-e45
pubmed: 27741031
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):221-5
pubmed: 22820805
BMC Public Health. 2016 May 04;16:373
pubmed: 27142727
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):e140-6
pubmed: 26258567
PLoS One. 2011;6(11):e27293
pubmed: 22114668
Pan Afr Med J. 2011;8:17
pubmed: 22121426
AIDS. 2009 Jan 28;23(3):395-401
pubmed: 19114865
J Int AIDS Soc. 2015 Jan 07;18:19305
pubmed: 25571857
AIDS. 2013 Feb 20;27(4):617-26
pubmed: 23364442
J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):437-42
pubmed: 22046601
PLoS Med. 2014 Dec 16;11(12):e1001768
pubmed: 25513807
AIDS Behav. 2013 Jun;17(5):1571-90
pubmed: 22752501
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
AIDS Behav. 2018 Aug;22(8):2458-2467
pubmed: 29754266
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):181-6
pubmed: 17667332
AIDS Patient Care STDS. 2010 Nov;24(11):735-41
pubmed: 21067357
PLoS One. 2011 Jan 31;6(1):e16488
pubmed: 21304973
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
Afr Health Sci. 2013 Jun;13(2):423-9
pubmed: 24235945
JAMA. 2017 Jun 6;317(21):2196-2206
pubmed: 28586888
Sex Transm Infect. 2012 Nov;88(7):498-503
pubmed: 22859498
PLoS Med. 2012;9(12):e1001351
pubmed: 23226107
J Int AIDS Soc. 2012 Sep 24;15(2):17352
pubmed: 23010377
Bull World Health Organ. 2012 Sep 1;90(9):652-658B
pubmed: 22984309
BMJ. 2013 Jun 13;346:f3481
pubmed: 23766483
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Lancet HIV. 2016 Mar;3(3):e111-9
pubmed: 26939734
Bull World Health Organ. 2011 May 1;89(5):328-335A
pubmed: 21556300
PLoS Med. 2013 Aug;10(8):e1001496
pubmed: 23966838
AIDS. 2013 Jan 28;27(3):417-25
pubmed: 22948271
BMC Public Health. 2010 Jun 23;10:362
pubmed: 20573215
PLoS One. 2014 Jul 11;9(7):e102267
pubmed: 25013938
AIDS Behav. 2017 Feb;21(2):547-560
pubmed: 27900501
PLoS One. 2015 Aug 14;10(8):e0135048
pubmed: 26275059
N Engl J Med. 2017 Nov 30;377(22):2154-2166
pubmed: 29171817
J Acquir Immune Defic Syndr. 2010 Oct;55(2):245-52
pubmed: 20714273
Trop Med Int Health. 2009 Aug;14(8):849-55
pubmed: 19552646
J Int AIDS Soc. 2015 Oct 14;18:20182
pubmed: 26471265
J Int AIDS Soc. 2013 Nov 14;16:18744
pubmed: 24241957
Trop Med Int Health. 2015 Jul;20(7):893-902
pubmed: 25753897
Lancet HIV. 2017 Feb;4(2):e74-e82
pubmed: 27913227
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):e83-e89
pubmed: 27846074
PLoS One. 2017 Oct 12;12(10):e0186316
pubmed: 29023510
Trop Med Int Health. 2017 Aug;22(8):1021-1029
pubmed: 28544728
PLoS Med. 2017 May 2;14(5):e1002292
pubmed: 28464041
PLoS One. 2014 Jan 02;9(1):e84317
pubmed: 24392124
Lancet Infect Dis. 2011 Jul;11(7):525-32
pubmed: 21546309
J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):625-30
pubmed: 21934554

Auteurs

Haddi Jatou Cham (HJ)

Division of Global HIV and TB, National Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Duncan MacKellar (D)

Division of Global HIV and TB, National Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Haruka Maruyama (H)

ICAP at Columbia University, Dar es Salaam, Tanzania.

Oscar Ernest Rwabiyago (OE)

U.S. Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.

Omari Msumi (O)

ICAP at Columbia University, Dar es Salaam, Tanzania.

Claire Steiner (C)

ICAP at Columbia University, Dar es Salaam, Tanzania.

Gerald Kundi (G)

ICAP at Columbia University, Dar es Salaam, Tanzania.

Rachel Weber (R)

U.S. Centers for Disease Control and Prevention, Yaounde, Cameroon.

Johnita Byrd (J)

ICF International, Atlanta, Georgia, United States of America.

Chutima Suraratdecha (C)

Division of Global HIV and TB, National Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Tewodaj Mengistu (T)

Division of Global HIV and TB, National Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Eliufoo Churi (E)

Henry Jackson Foundation Medical Research International, Mbeya, Tanzania.

Sherri Pals (S)

Division of Global HIV and TB, National Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Caitlin Madevu-Matson (C)

ICAP at Columbia University, New York, New York, United States of America.

Geofrey Alexander (G)

Tanzania Health Promotion Support, Dar es Salaam, Tanzania.

Sarah Porter (S)

Division of Global HIV and TB, National Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Kokuhumbya Kazaura (K)

U.S. Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.

Deogratius Mbilinyi (D)

United Nations Children's Fund, Dar es Salaam, Tanzania.

Fernando Morales (F)

ICAP at Columbia University, Dar es Salaam, Tanzania.

Thomas Rutachunzibwa (T)

Ministry of Health, Community Development, Gender, Elderly and Children, Bukoba, Tanzania.

Jessica Justman (J)

Tanzania Health Promotion Support, Dar es Salaam, Tanzania.

Anath Rwebembera (A)

National AIDS Control Program, Ministry of Health, Community Development, Gender, Elderly and Children, Dar es Salaam, Tanzania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH